Free Trial

Relmada Therapeutics (RLMD) News Today

$4.06
-0.30 (-6.88%)
(As of 07/12/2024 ET)
Relmada Therapeutics logo with Medical background
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Down 34.8% in June
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,010,000 shares, a decline of 34.8% from the June 15th total of 1,550,000 shares. Based on an average daily volume of 104,700 shares, the days-to-cover ratio is currently 9.6 days.
Relmada Therapeutics (NASDAQ:RLMD) Shares Up 5.6%
Relmada Therapeutics logo with Medical background
Opaleye Management Inc. Purchases 847,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD)
Opaleye Management Inc. grew its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) by 2,823.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 877,000 shares of the company's stock after acquiring an additio
The Goldman Sachs Group Downgrades Relmada Therapeutics (NASDAQ:RLMD) to Sell
The Goldman Sachs Group downgraded shares of Relmada Therapeutics from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $3.00 to $2.00 in a research note on Wednesday.
Relmada Therapeutics (NASDAQ:RLMD) Trading Up 2.7%
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Up 2.7%
7 Penny Biotech Stocks to Triple Your Investment
Q1 2024 Relmada Therapeutics Inc Earnings Call
Relmada Therapeutics (RLMD) Set to Announce Quarterly Earnings on Wednesday
Relmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3%
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 3.3%
RELMADA THERAPEUT.DL-,001 (4E2.F)
Q4 2023 Relmada Therapeutics Inc Earnings Call
Recap: Relmada Therapeutics Q4 Earnings
RLMD Apr 2024 2.500 put
Silverarc Capital Management LLC Acquires Shares of 100,000 Relmada Therapeutics, Inc. (NASDAQ:RLMD)
Silverarc Capital Management LLC acquired a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company's stock,
Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc.
FY2024 Earnings Forecast for Relmada Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RLMD)
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of Relmada Therapeutics in a note issued to investors on Monday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post
Leerink Partnrs Weighs in on Relmada Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:RLMD)
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Investment analysts at Leerink Partnrs issued their FY2028 earnings estimates for shares of Relmada Therapeutics in a research report issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will post
Relmada Therapeutics Inc RLMD
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Down 26.2% in December
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 638,800 shares, a decrease of 26.2% from the November 30th total of 865,800 shares. Based on an average trading volume of 172,800 shares, the days-to-cover ratio is presently 3.7 days.
Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Don’t say I didn’t warn you… (Ad)

All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.

To see Porter Stansberry's new AI prediction go here now.

RLMD Media Mentions By Week

RLMD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLMD
News Sentiment

0.49

0.92

Average
Medical
News Sentiment

RLMD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLMD Articles
This Week

4

1

RLMD Articles
Average Week

Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RLMD) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners